Dendritic cells drive next-generation checkpoint blockade immunotherapy.

Two next-generation checkpoint blockade strategies act through mature conventional type 1 dendritic cells (cDC1s), which assemble costimulatory signals that shape CD8+ T cell fate and efficacy.

• Why it matters: Checkpoint therapies depend on how antitumor T cell responses are initiated and programmed, but the specific cellular steps linking checkpoint engagement to CD8+ T cell outcomes were unclear.
• What they did: Luri-Rey et al. and Duong et al. tested two next-generation checkpoint approaches and found they require mature cDC1s that provide the costimulatory signals governing CD8+ T cell fate.
• The result: By identifying mature cDC1s as the key mediators, the work suggests these checkpoint strategies’ therapeutic performance is tied to cDC1-driven costimulation.

AI summary of the abstract · may contain errors · not medical advice · read the paper.